Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy
- PMID: 32477593
- PMCID: PMC7243302
- DOI: 10.1186/s40959-020-00060-0
Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy
Abstract
Background: Anthracyclines are a mainstay of chemotherapy. However, a relatively frequent adverse outcome of anthracycline treatment is cardiomyopathy. Multiple genetic studies have begun to dissect the complex genetics underlying cardiac sensitivity to the anthracycline drug class. A number of single nucleotide polymorphisms (SNPs) have been identified to be in linkage disequilibrium with anthracycline induced cardiotoxicity in paediatric populations.
Methods: Here we screened for the presence of SNPs resulting in a missense coding change in a cohort of children with early onset chemotherapy related cardiomyopathy. The SNP identity was evaluated by Sanger sequencing of PCR amplicons from genomic DNA of patients with anthracycline related cardiac dysfunction.
Results: All of the published SNPs were observed within our patient group. There was no correlation between the number of missense variants an individual carried with severity of disease. Furthermore, the time to cardiac disease onset post-treatment was not greater in those individuals carrying a high load of SNPs resulting from missense variants.
Conclusions: We conclude that previously identified missense SNPs are present within a paediatric cohort with early onset heart damage induced by anthracyclines. However, these SNPs require further replication cohorts and functional validation before being deployed to assess anthracycline cardiotoxicity risk in the clinic.
Keywords: Anthracycline induced cardiomyopathy; Genetic variants; Paediatric cancers.
© The Author(s) 2020.
Conflict of interest statement
Competing interestsThe authors have no competing interests to declare.
Similar articles
-
Polymorphisms rs4673 and rs28714259 in predicting anthracycline-mediated cardiotoxicity in patients with breast cancer.Klin Onkol. 2021 Fall;34(6):463-466. doi: 10.48095/ccko2021463. Klin Onkol. 2021. PMID: 34911332 English.
-
HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.Cardiovasc Toxicol. 2021 Jan;21(1):59-66. doi: 10.1007/s12012-020-09595-1. Epub 2020 Aug 3. Cardiovasc Toxicol. 2021. PMID: 32748118
-
Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.Breast Cancer Res Treat. 2018 Jan;167(1):249-256. doi: 10.1007/s10549-017-4497-9. Epub 2017 Sep 14. Breast Cancer Res Treat. 2018. PMID: 28913729
-
Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.Paediatr Drugs. 2005;7(2):67-76. doi: 10.2165/00148581-200507020-00001. Paediatr Drugs. 2005. PMID: 15871628 Review.
-
Epidemiology of anthracycline cardiotoxicity in children and adults.Semin Oncol. 1998 Aug;25(4 Suppl 10):72-85. Semin Oncol. 1998. PMID: 9768828 Review.
Cited by
-
Organoids are not organs: Sources of variation and misinformation in organoid biology.Stem Cell Reports. 2023 Jun 13;18(6):1255-1270. doi: 10.1016/j.stemcr.2023.05.009. Stem Cell Reports. 2023. PMID: 37315519 Free PMC article. Review.
-
Modeling Susceptibility to Cardiotoxicity in Cancer Therapy Using Human iPSC-Derived Cardiac Cells and Systems Biology.Heart Fail Clin. 2022 Jul;18(3):335-347. doi: 10.1016/j.hfc.2022.02.009. Heart Fail Clin. 2022. PMID: 35718410 Free PMC article. Review.
-
Role of GPCR Signaling in Anthracycline-Induced Cardiotoxicity.Cells. 2025 Jan 22;14(3):169. doi: 10.3390/cells14030169. Cells. 2025. PMID: 39936961 Free PMC article. Review.
-
Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk.Cells. 2023 Jul 27;12(15):1956. doi: 10.3390/cells12151956. Cells. 2023. PMID: 37566035 Free PMC article.
-
Leveraging Clinical Informatics Tools to Extract Cumulative Anthracycline Exposure, Measure Cardiovascular Outcomes, and Assess Guideline Adherence for Children With Cancer.JCO Clin Cancer Inform. 2021 Oct;5:1062-1075. doi: 10.1200/CCI.21.00099. JCO Clin Cancer Inform. 2021. PMID: 34714665 Free PMC article.
References
-
- Bonadonna G, Monfardini S. Cardiac toxicity of daunorubicin. Lancet (London, England) 1969;1(7599):837. - PubMed
-
- Von Hoff DD, Layard MW, Basa P, Davis HL, Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–717. - PubMed
-
- Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR et al: SEER Cancer Statistics Review, 1975–2016. In. Edited by Institute. NC. Bethesda, MD: NIH; 2019.
LinkOut - more resources
Full Text Sources